» Articles » PMID: 11342300

What Can We Learn from Leukemia As for the Process of Lineage Commitment in Hematopoiesis?

Overview
Journal Int Rev Immunol
Publisher Informa Healthcare
Date 2001 May 9
PMID 11342300
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Most contemporary models of hematopoiesis assume lineage fidelity of early progenitor cells. Along with this concept normal hematopoietic cells and the majority of leukemias express exclusively myeloid or lymphoid specific antigens. On the other hand, growing evidence exists challenging the lineage fidelity model. Chronic myeloid leukemia (CML) in the blast crisis may switch to acute lymphoblastic leukemia (ALL) and as a result of the chemotherapy ALL may converse to acute myeloid leukemia (AML). Furthermore, a substantial portion of leukemia cases, named acute mixed-lineage leukemia (AMLL), show simultaneous expression of both myeloid and lymphoid antigens. Immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements, correlating with myeloid-lymphoid immunophenotype in AMLL, support the hypothesis of lineage infidelity of early progenitor cells, rather than the aberrant antigen expression. Based on a detailed characterization of AMLL we present a modified model of a "common myeloid/lymphoid progenitor cell". This hypothetical very early hematopoietic progenitor cell shows a transient expression of myeloid and B- or T-lymphoid antigen and may also have rearranged its Ig and/or TCR genes. Subsequently, myeloid or lymphoid markers are downregulated and the hematopoietic cell enters either myeloid, T-lymphoid or B-lymphoid differentiation pathway.

Citing Articles

Myeloid/Lymphoid Neoplasms with Fusion Gene: A Rare Case of Poor Response to Imatinib and Possible Transformation Mechanisms from Myeloid Neoplasms of Bone Marrow to T-Cell Lymphoblastic Lymphoma Invasion in Lymph Nodes.

Gou Y, Tang Y, Liu S, Cheng S, Deng X, Wen Q J Inflamm Res. 2023; 16:5163-5170.

PMID: 38026242 PMC: 10649033. DOI: 10.2147/JIR.S427995.


Mechanisms of Immunosuppressive Tumor Evasion: Focus on Acute Lymphoblastic Leukemia.

Jimenez-Morales S, Aranda-Uribe I, Perez-Amado C, Ramirez-Bello J, Hidalgo-Miranda A Front Immunol. 2021; 12:737340.

PMID: 34867958 PMC: 8636671. DOI: 10.3389/fimmu.2021.737340.


Gata3 restrains B cell proliferation and cooperates with p18INK4c to repress B cell lymphomagenesis.

Liu S, Chan H, Bai F, Ma J, Scott A, Robbins D Oncotarget. 2016; 7(39):64007-64020.

PMID: 27588406 PMC: 5325421. DOI: 10.18632/oncotarget.11746.


A functional polymorphism in the CEBPE gene promoter influences acute lymphoblastic leukemia risk through interaction with the hematopoietic transcription factor Ikaros.

Wiemels J, de Smith A, Xiao J, Lee S, Muench M, Fomin M Leukemia. 2015; 30(5):1194-7.

PMID: 26437776 PMC: 4794412. DOI: 10.1038/leu.2015.251.


Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?.

Schulenburg A, Blatt K, Cerny-Reiterer S, Sadovnik I, Herrmann H, Marian B J Hematol Oncol. 2015; 8:16.

PMID: 25886184 PMC: 4345016. DOI: 10.1186/s13045-015-0113-9.